Email: cspc@cspc.cn
Media
News Center
Mar. 04
2026
VOLUNTARY ANNOUNCEMENT - EMICIZUMAB INJECTION (SYS6053) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar. 02
VOLUNTARY ANNOUNCEMENT - PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION, RAPID SUSPENSION (ALBUMIN-BOUND) (SYHX2011G1) OBTAINS CLINICAL TRIAL APPR
Feb. 16
VOLUNTARY ANNOUNCEMENT - ROPIVACAINE LONG-ACTING INJECTION (SYH9089 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
VOLUNTARY ANNOUNCEMENT - GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE LONG-ACTING INJECTION (SYH2082 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S
Feb. 02
VOLUNTARY ANNOUNCEMENT - CLEVIDIPINE INJECTABLE EMULSION OBTAINS DRUG REGISTRATION APPROVAL
Jan. 30
VOLUNTARY ANNOUNCEMENT - ENTERING INTO A STRATEGIC COLLABORATION AND LICENSE AGREEMENT WITH ASTRAZENECA FOR THE DEVELOPMENT OF INNOVATIVE LONG-ACTING PEPTIDE ME
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
